PARIS, France – September 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing ...
The issuer is solely responsible for the content of this announcement. Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic ...
Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational ...
- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ...
Abstract: Class-incremental semantic segmentation (CSS) aims to continuously classify every pixel in an image to its corresponding semantic class. Existing CSS models suffer from two challenges: ...
Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 to ...
Naturally occurring perlecan domain V LG3 ("PDV LG3 ") is considered to be a powerful component of the body's innate mechanism for neurovascular preservation and restoration following injury. It is a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely targets tumors, today announced an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback